Palatin Technologies (PTN) Cash from Operations (2010 - 2026)
Palatin Technologies' (PTN) quarterly Cash from Operations came in at -$4.4 million in Q1 2026, up 17.5% on a YoY basis from -$3.8 million in Q1 2025, and up 8.11% quarter-over-quarter from -$4.8 million in Q4 2025.
Analysis
Palatin Technologies (PTN) Cash from Operations (2010 - 2026) Analysis & Trends
Palatin Technologies (PTN) has reported Cash from Operations for 17 consecutive years, with -$4.4 million the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations rose 17.5% year-over-year to -$4.4 million; the trailing twelve-month figure through Mar 2026 stood at -$14.9 million (up 36.97% YoY), and the FY2025 full-year result was -$21.3 million, up 32.28% from the prior year.
- Cash from Operations advanced to -$4.4 million in Q1 2026 per PTN's latest filing, from -$4.8 million in the prior quarter.
- Across five years, Cash from Operations topped out at -$1.4 million in Q1 2023 and bottomed at -$10.5 million in Q4 2023.
- Historically, Cash from Operations has averaged -$6.5 million across 5 years, with a median of -$6.5 million in 2024.
- The sharpest annual moves came in 2022 and 2023: Cash from Operations slumped 4140.77% in 2022, then surged 85.16% in 2023.
- Over 5 years, Cash from Operations stood at -$9.7 million in 2022, then declined by 8.27% to -$10.5 million in 2023, then surged by 53.73% to -$4.8 million in 2024, then advanced by 0.83% to -$4.8 million in 2025, then gained by 8.11% to -$4.4 million in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered -$4.4 million, -$4.8 million, and -$1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 4.00 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 3.57 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.13 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 813.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -526.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 448.90 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -270.50 Mn |
| 10 | Palatin Technologies | 46.98 Mn | 46.98 Mn | - | -4.42 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -4.42 Mn |
| Dec 31, 2025 | -4.81 Mn |
| Sep 30, 2025 | -1.62 Mn |
| Jun 30, 2025 | -4.09 Mn |
| Mar 31, 2025 | -5.35 Mn |
| Dec 31, 2024 | -4.85 Mn |
| Sep 30, 2024 | -7.02 Mn |
| Jun 30, 2024 | -6.47 Mn |
| Mar 31, 2024 | -8.61 Mn |
| Dec 31, 2023 | -10.48 Mn |
| Sep 30, 2023 | -5.91 Mn |
| Jun 30, 2023 | -9.61 Mn |
| Mar 31, 2023 | -1.41 Mn |
| Dec 31, 2022 | -9.68 Mn |
| Sep 30, 2022 | -8.58 Mn |
| Jun 30, 2022 | -7.72 Mn |
| Mar 31, 2022 | -9.49 Mn |
| Dec 31, 2021 | -12.51 Mn |
| Sep 30, 2021 | -202,353.00 |
| Jun 30, 2021 | 14.02 Mn |